116 related articles for article (PubMed ID: 24158596)
1. [Bone targeted therapies: new agents].
Barth C; Massard C; Vignot S
Bull Cancer; 2013 Nov; 100(11):1215-21. PubMed ID: 24158596
[TBL] [Abstract][Full Text] [Related]
2. An update on dual Src/Abl inhibitors.
Musumeci F; Schenone S; Brullo C; Botta M
Future Med Chem; 2012 Apr; 4(6):799-822. PubMed ID: 22530642
[TBL] [Abstract][Full Text] [Related]
3. [Molecular basis of bone metastasis formation and its targeted therapy].
Tímár J
Magy Onkol; 2010 Mar; 54(1):59-64. PubMed ID: 20350869
[TBL] [Abstract][Full Text] [Related]
4. [SRC kinases in tumor therapy].
Dempke W; Zippel R
Med Klin (Munich); 2010 Oct; 105(10):711-5. PubMed ID: 20981590
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in bone-targeted therapies of metastatic prostate cancer.
Deng X; He G; Liu J; Luo F; Peng X; Tang S; Gao Z; Lin Q; Keller JM; Yang T; Keller ET
Cancer Treat Rev; 2014 Jul; 40(6):730-8. PubMed ID: 24767837
[TBL] [Abstract][Full Text] [Related]
6. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Schenone S; Brullo C; Musumeci F; Botta M
Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
[TBL] [Abstract][Full Text] [Related]
7. Current status of SRC inhibitors in solid tumor malignancies.
Puls LN; Eadens M; Messersmith W
Oncologist; 2011; 16(5):566-78. PubMed ID: 21521831
[TBL] [Abstract][Full Text] [Related]
8. Future directions of bone-targeted therapy for metastatic breast cancer.
Onishi T; Hayashi N; Theriault RL; Hortobagyi GN; Ueno NT
Nat Rev Clin Oncol; 2010 Nov; 7(11):641-51. PubMed ID: 20808302
[TBL] [Abstract][Full Text] [Related]
9. Anti-resorptive therapies for osteoporosis.
Reid IR
Semin Cell Dev Biol; 2008 Oct; 19(5):473-8. PubMed ID: 18760372
[TBL] [Abstract][Full Text] [Related]
10. [Bone remodeling: new therapeutic approaches].
Ferrari S
Rev Med Suisse; 2009 Jun; 5(207):1325-8. PubMed ID: 19626933
[TBL] [Abstract][Full Text] [Related]
11. [Encounter of cancer cells with bone. Development of bone metastasis-specific targeting therapy].
Hayashi S; Hanamura T
Clin Calcium; 2011 Mar; 21(3):389-96. PubMed ID: 21358060
[TBL] [Abstract][Full Text] [Related]
12. Future developments in osteoporosis therapy.
Ng KW
Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):371-84. PubMed ID: 19857200
[TBL] [Abstract][Full Text] [Related]
13. [Osteoporosis].
Miyamoto T; Toyama Y
Nihon Rinsho; 2012 Nov; 70 Suppl 8():623-7. PubMed ID: 23513914
[No Abstract] [Full Text] [Related]
14. New approaches to the treatment of osteoporosis.
Silva BC; Bilezikian JP
Annu Rev Med; 2011; 62():307-22. PubMed ID: 21054170
[TBL] [Abstract][Full Text] [Related]
15. New approaches to treating and preventing bone metastases.
Lipton A
Curr Opin Support Palliat Care; 2010 Sep; 4(3):178-81. PubMed ID: 20703154
[TBL] [Abstract][Full Text] [Related]
16. [Current topics in drug therapy aiming at bone resorption].
Yasui T; Tanaka S
Clin Calcium; 2006 Sep; 16(9):1475-79. PubMed ID: 16951471
[TBL] [Abstract][Full Text] [Related]
17. Src as a therapeutic target in men with prostate cancer and bone metastases.
Saad F
BJU Int; 2009 Feb; 103(4):434-40. PubMed ID: 19154462
[TBL] [Abstract][Full Text] [Related]
18. Are cathepsin k inhibitors just another class of anti-resorptives?
Chambers TJ; Tobias JH
J Clin Endocrinol Metab; 2013 Nov; 98(11):4329-31. PubMed ID: 24057285
[No Abstract] [Full Text] [Related]
19. Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib.
Redaelli S; Boschelli F; Perini P; Pirola A; Viltadi M; Gambacorti-Passerini C
Leukemia; 2010 Jun; 24(6):1223-7. PubMed ID: 20445575
[No Abstract] [Full Text] [Related]
20. Novel approaches to the treatment of osteoporosis.
Appelman-Dijkstra NM; Papapoulos SE
Best Pract Res Clin Endocrinol Metab; 2014 Dec; 28(6):843-57. PubMed ID: 25432356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
